Abstract:The nanocarriers are administered intravenously via the tail vein and primarily eliminated by the kidneys. However, during the elimination process, it undergoes reabsorption in the renal tubules, leading to renal enrichment. This approach can serve as an effective renal delivery vector for siRNA and prevent and alleviate related kidney diseases. With the emergence of gene therapy utilizing viral vectors, the potential risks associated with these vectors have prompted increased attention toward non‐viral alternatives. DNA nanotechnology enables the assembly of specific oligonucleotide chains into nanostructures possessing defined spatial configurations. Due to their inherent characteristics, DNA nanostructures possess natural advantages as carriers for regulating gene expression in a non‐viral manner. Cholesterol modification can convert DNA nanostructures from hydrophilic materials to amphiphilic materials, thereby extending their systemic circulation time. In this study, the high‐dimensional design and cholesterol modification are shown to prolong the systemic circulation half‐life of DNA nanostructures in mice. Specifically, the tetrahedron structure modified with three cholesterol molecules (TDN‐3Chol) exhibit excellent circulation time and demonstrate a preference for renal uptake. The unique characteristics of TDN‐3Chol can effectively deliver p53 siRNA to the mouse renal tubular tissue, resulting in successful knockdown of p53 and demonstrating its potential for preventing acute kidney injury. Furthermore, TDN‐3Chol is not exhibited significant toxicity in mice, highlighting its promising role as a non‐viral vector for targeted gene expression regulation in the kidneys. The designed non‐viral vector as a prophylactic medication shows potential in addressing the current clinical challenges associated with nephrotoxic drugs.

Chapter 11 siRNA-Induced RNAi Therapy in Acute Kidney Injury

Fighting Against Kidney Diseases with Small Interfering RNA: Opportunities and Challenges

Kidney Targeted Delivery of Sirna Mediated by Peptide-Sirna Conjugate for the Treatment of Acute Kidney Injury

Preventing tissue injury using siRNA.

Rna Interference: A Potent Tool for Gene-Specific Therapeutics

Kim-1 Targeted Extracellular Vesicles: A New Therapeutic Platform for RNAi to Treat AKI

Therapeutic siRNA: State-of-the-Art and Future Perspectives

Inulin-based nanoparticles for targeted siRNA delivery in acute kidney injury

Cholesterol‐Modified DNA Nanostructures Serve as Effective Non‐Viral Carriers for Delivering siRNA to the Kidneys to Prevent Acute Kidney Injury

Renal subcapsular infusion of siRNA as a novel method of gene silencing in the kidney

Attenuating Ischemia-Reperfusion Injury in Kidney Transplantation by Perfusing Donor Organs With siRNA Cocktail Solution.

Current progress of siRNA/shRNA therapeutics in clinical trials

Use of RNA interference to minimize ischemia reperfusion injury.

Subcellular Fate and Off-Target Effects of siRNA, shRNA, and miRNA

Therapeutic Potentials of Gene Silencing by RNA Interference: Principles, Challenges, and New Strategies.

Recent Advances in Engineering Carriers for siRNA Delivery

Therapeutic targeting in the silent era: advances in non-viral siRNA delivery.

Strategies, design, and chemistry in siRNA delivery systems

RNAi-based drug design: considerations and future directions

Overcoming Barriers for siRNA Therapeutics: From Bench to Bedside

A new approach for therapeutic use by RNA interference in the brain